Pulmonary arterial hypertension (PAH) is a cardiovascular disorder characterised by pulmonary vascular remodelling resulting in increased pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), which can lead to progressive right heart failure [1, 2]. Right heart catheterisation (RHC) remains the gold standard for the diagnosis of pulmonary hypertension (PH) [1, 2]. Furthermore, several haemodynamic variables are included in the multiparametric model used at baseline to assess the risk of death [1, 2]. At follow-up, it is recommended to assess at least World Health Organization/New York Heart Association Functional Class (WHO/NYHA FC), 6-min walk distance (6MWD) and biomarkers (brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP)) to establish the risk status according to the non-invasive four-strata model [1, 2]. Additional variables such as haemodynamics should be considered as needed. It is left to the discretion of the physician to carry out RHC [1, 2]. However, it is not clear which patients should benefit from this examination.

肺动脉高压(PAH)是一种心血管疾病，其特征是肺血管重塑导致肺动脉压(PAP)和肺血管阻力(PVR)增加，可导致进行性右心衰竭[1, 2]。右心导管插入术 (RHC) 仍然是诊断肺动脉高压 (PH) 的金标准 [1, 2]。此外，基线时使用的多参数模型中包含几个血液动力学变量，用于评估死亡风险 [1, 2]。随访时，建议至少评估世界卫生组织/纽约心脏协会功能等级 (WHO/NYHA FC)、6 分钟步行距离 (6MWD) 和生物标志物（脑钠尿肽 (BNP) 或 N 末端） pro-BNP (NT-proBNP)) 根据无创四层模型建立风险状态 [1, 2]。应根据需要考虑其他变量，例如血流动力学。是否进行 RHC 由医生自行决定 [1, 2]。然而，尚不清楚哪些患者应该从这项检查中受益。